Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2011

01.04.2011 | Urologic Oncology

Impact of Elective Versus Imperative Indications on Oncologic Outcomes After Open Nephron-Sparing Surgery for the Treatment of Sporadic Renal Cell Carcinomas

verfasst von: Grégoire Coffin, MD, Vincent Hupertan, MD, Lionel Taksin, MD, Christophe Vaessen, MD, Emmanuel Chartier-Kastler, MD, PhD, Marc-Olivier Bitker, MD, PhD, Morgan Rouprêt, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the effect of nephron-sparing surgery (NSS) on cancer control in renal cell carcinomas (RCC) and to compare the outcomes of patients who had elective versus imperative indications for surgery.

Methods

We performed a retrospective review of the data for patients treated with open NSS between 1980 and 2005 for sporadic RCCs. The following data were analyzed: age, intraoperative parameters, tumor size, Fuhrman grade, tumor, node, metastasis system disease stage, pathological data, and outcome.

Results

A total of 155 patients with a median age of 60 years were included. The mean preoperative and postoperative creatinine levels were 1.1 ± 0.3 mg/dl (range 0.6–2.6 mg/dl) and 1.2 ± 0.4 mg/dl (range 0.5–3.4 mg/dl), respectively. The mean tumor size was 3.8 ± 2 cm (range 1–10 cm). Margin status was positive in 15 cases (9.70%), and multifocal RCCs were observed in 36 patients (23.2%). Overall, NSS indications were elective in 96 cases (61.9%) and imperative in 59 cases (38.1%). Univariate analysis found that elective cases were associated with better perioperative outcomes (P = 0.01). In univariate analysis, tumor, node, metastasis system disease stage, multifocality, and indication were associated with recurrence (P < 0.05). In the multivariate analysis, only multifocality status and imperatives indications were significant (P < 0.05). The mean follow-up was 118.2 ± 151 months. The 5- and 10-year tumor-free survival rates were 81.8% and 78.7% in elective and imperatives cases, respectively.

Conclusions

Oncologic control seems to be better for cases of elective open NSS. Thus, NSS should be advocated as soon as it is technically possible, regardless of the size of the tumor.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef
2.
Zurück zum Zitat Antonelli A, Cozzoli A, Nicolai M, et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm. Eur Urol. 2008;53:803–9.PubMedCrossRef Antonelli A, Cozzoli A, Nicolai M, et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm. Eur Urol. 2008;53:803–9.PubMedCrossRef
3.
Zurück zum Zitat Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502–10.PubMedCrossRef Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502–10.PubMedCrossRef
4.
Zurück zum Zitat Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol. 2003;170:764–7.PubMedCrossRef Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol. 2003;170:764–7.PubMedCrossRef
5.
Zurück zum Zitat Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236–42.PubMedCrossRef Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236–42.PubMedCrossRef
6.
Zurück zum Zitat Mitchell RE, Gilbert SM, Murphy AM, et al. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006;67:260–4.PubMedCrossRef Mitchell RE, Gilbert SM, Murphy AM, et al. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006;67:260–4.PubMedCrossRef
7.
Zurück zum Zitat Pasticier G, Timsit MO, Badet L, et al. Nephron-sparing surgery for renal cell carcinoma: detailed analysis of complications over a 15-year period. Eur Urol. 2006;49:485–90.PubMedCrossRef Pasticier G, Timsit MO, Badet L, et al. Nephron-sparing surgery for renal cell carcinoma: detailed analysis of complications over a 15-year period. Eur Urol. 2006;49:485–90.PubMedCrossRef
8.
Zurück zum Zitat Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7:735–40.PubMedCrossRef Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7:735–40.PubMedCrossRef
9.
Zurück zum Zitat Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000;163:730–6.PubMedCrossRef Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000;163:730–6.PubMedCrossRef
10.
Zurück zum Zitat Novick AC, Streem S, Montie JE, et al. Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. 1989. J Urol. 2002;167:878–83. Novick AC, Streem S, Montie JE, et al. Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. 1989. J Urol. 2002;167:878–83.
11.
Zurück zum Zitat Pahernik S, Roos F, Hampel C, et al. Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney:25 years of experience. J Urol. 2006;175:2027–31.PubMedCrossRef Pahernik S, Roos F, Hampel C, et al. Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney:25 years of experience. J Urol. 2006;175:2027–31.PubMedCrossRef
12.
Zurück zum Zitat Ghavamian R, Cheville JC, Lohse CM, et al. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol. 2002;168:454–9.PubMedCrossRef Ghavamian R, Cheville JC, Lohse CM, et al. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol. 2002;168:454–9.PubMedCrossRef
13.
Zurück zum Zitat Dash A, Vickers AJ, Schachter LR, et al. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm. BJU Int. 2006;97:939–45.PubMedCrossRef Dash A, Vickers AJ, Schachter LR, et al. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm. BJU Int. 2006;97:939–45.PubMedCrossRef
14.
Zurück zum Zitat Denzinger S, Ganzer R, Fink A, et al. Open partial nephrectomy for imperative and elective indications comparison of peri-operative data and long-term follow-up. Scand J Urol Nephrol. 2007;41:496–500.PubMedCrossRef Denzinger S, Ganzer R, Fink A, et al. Open partial nephrectomy for imperative and elective indications comparison of peri-operative data and long-term follow-up. Scand J Urol Nephrol. 2007;41:496–500.PubMedCrossRef
15.
Zurück zum Zitat Haferkamp A, Kurosch M, Pritsch M, et al. Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications. Ann Surg Oncol. 2010;17:544–51.PubMedCrossRef Haferkamp A, Kurosch M, Pritsch M, et al. Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications. Ann Surg Oncol. 2010;17:544–51.PubMedCrossRef
16.
Zurück zum Zitat Kural AR, Demirkesen O, Onal B, et al. Outcome of nephron-sparing surgery: elective versus imperative indications. Urol Int. 2003;71:190–6.PubMedCrossRef Kural AR, Demirkesen O, Onal B, et al. Outcome of nephron-sparing surgery: elective versus imperative indications. Urol Int. 2003;71:190–6.PubMedCrossRef
17.
Zurück zum Zitat Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. Urological tumours. 7th rev. New York: Wiley-Blackwell/UICC, 2009; p. 237–66. Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. Urological tumours. 7th rev. New York: Wiley-Blackwell/UICC, 2009; p. 237–66.
18.
Zurück zum Zitat Roupret M, Hopirtean V, Mejean A, et al. Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau’s disease: a single center experience. J Urol. 2003;170:1752–5.PubMedCrossRef Roupret M, Hopirtean V, Mejean A, et al. Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau’s disease: a single center experience. J Urol. 2003;170:1752–5.PubMedCrossRef
19.
Zurück zum Zitat Peycelon M, Hupertan V, Comperat E, et al. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. 2009;181:35–41.PubMedCrossRef Peycelon M, Hupertan V, Comperat E, et al. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. 2009;181:35–41.PubMedCrossRef
20.
Zurück zum Zitat Patard JJ, Pantuck AJ, Crepel M, et al. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol. 2007;52:148–54.PubMedCrossRef Patard JJ, Pantuck AJ, Crepel M, et al. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol. 2007;52:148–54.PubMedCrossRef
21.
Zurück zum Zitat Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171:2181–5.PubMedCrossRef Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171:2181–5.PubMedCrossRef
22.
Zurück zum Zitat Bensalah K, Crepel M, Patard JJ, Tumor size and nephron-sparing surgery: does it still matter? Eur Urol. 2008;53:691–3.PubMedCrossRef Bensalah K, Crepel M, Patard JJ, Tumor size and nephron-sparing surgery: does it still matter? Eur Urol. 2008;53:691–3.PubMedCrossRef
23.
Zurück zum Zitat Sutherland SE, Resnick MI, Maclennan GT, et al. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol. 2002;167:61–4.PubMedCrossRef Sutherland SE, Resnick MI, Maclennan GT, et al. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol. 2002;167:61–4.PubMedCrossRef
24.
Zurück zum Zitat McKiernan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816–20.PubMedCrossRef McKiernan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816–20.PubMedCrossRef
25.
Zurück zum Zitat Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010;57:466–71.PubMedCrossRef Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010;57:466–71.PubMedCrossRef
26.
Zurück zum Zitat Raz O, Mendlovic S, Shilo Y, et al. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery. Urology. 2010;75:277–80.PubMedCrossRef Raz O, Mendlovic S, Shilo Y, et al. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery. Urology. 2010;75:277–80.PubMedCrossRef
27.
Zurück zum Zitat Song C, Bang JK, Park HK, et al. Factors influencing renal function reduction after partial nephrectomy. J Urol. 2009;181:48–54.PubMedCrossRef Song C, Bang JK, Park HK, et al. Factors influencing renal function reduction after partial nephrectomy. J Urol. 2009;181:48–54.PubMedCrossRef
28.
Zurück zum Zitat Timsit MO, Bazin JP, Thiounn N, et al. Prospective study of safety margins in partial nephrectomy: intraoperative assessment and contribution of frozen section analysis. Urology. 2006;67:923–6.PubMedCrossRef Timsit MO, Bazin JP, Thiounn N, et al. Prospective study of safety margins in partial nephrectomy: intraoperative assessment and contribution of frozen section analysis. Urology. 2006;67:923–6.PubMedCrossRef
29.
Zurück zum Zitat Neuzillet Y, Long JA, Paparel P, et al. Clamping modalities during partial nephrectomy: technical aspects and functional consequences. Review by the Comite de cancerologie de l’Association francaise d’urologie (CCAFU). Prog Urol. 2009;19:524–9.PubMedCrossRef Neuzillet Y, Long JA, Paparel P, et al. Clamping modalities during partial nephrectomy: technical aspects and functional consequences. Review by the Comite de cancerologie de l’Association francaise d’urologie (CCAFU). Prog Urol. 2009;19:524–9.PubMedCrossRef
30.
Zurück zum Zitat Lida S, Kondo T, Amano H, et al. Minimal effect of cold ischemia time on progression to late-stage chronic kidney disease observed long term after partial nephrectomy. Urology. 2008;72:1083–9.CrossRef Lida S, Kondo T, Amano H, et al. Minimal effect of cold ischemia time on progression to late-stage chronic kidney disease observed long term after partial nephrectomy. Urology. 2008;72:1083–9.CrossRef
31.
Zurück zum Zitat Joniau S, Vander Eeckt K, Srirangam SJ, et al. Outcome of nephron-sparing surgery for T1b renal cell carcinoma. BJU Int. 2009;103:1344–8.PubMedCrossRef Joniau S, Vander Eeckt K, Srirangam SJ, et al. Outcome of nephron-sparing surgery for T1b renal cell carcinoma. BJU Int. 2009;103:1344–8.PubMedCrossRef
32.
Zurück zum Zitat Funahashi Y, Hattori R, Yamamoto T, et al. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol. 2009;55:209–15.PubMedCrossRef Funahashi Y, Hattori R, Yamamoto T, et al. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol. 2009;55:209–15.PubMedCrossRef
33.
Zurück zum Zitat Rouach Y, Delongchamps NB, Patey N, et al. Suture or hemostatic agent during laparoscopic partial nephrectomy? A randomized study using a hypertensive porcine model. Urology. 2009;73:172–7.PubMedCrossRef Rouach Y, Delongchamps NB, Patey N, et al. Suture or hemostatic agent during laparoscopic partial nephrectomy? A randomized study using a hypertensive porcine model. Urology. 2009;73:172–7.PubMedCrossRef
34.
Zurück zum Zitat Benway BM, Bhayani SB, Rogers CG, et al. Robot-assisted partial nephrectomy: an international experience. Eur Urol. 2010;57:815–20.PubMedCrossRef Benway BM, Bhayani SB, Rogers CG, et al. Robot-assisted partial nephrectomy: an international experience. Eur Urol. 2010;57:815–20.PubMedCrossRef
35.
Zurück zum Zitat Gill IS, Colombo JR, Jr., Frank I, et al. Laparoscopic partial nephrectomy for hilar tumors. J Urol. 2005;174:850–4.PubMedCrossRef Gill IS, Colombo JR, Jr., Frank I, et al. Laparoscopic partial nephrectomy for hilar tumors. J Urol. 2005;174:850–4.PubMedCrossRef
Metadaten
Titel
Impact of Elective Versus Imperative Indications on Oncologic Outcomes After Open Nephron-Sparing Surgery for the Treatment of Sporadic Renal Cell Carcinomas
verfasst von
Grégoire Coffin, MD
Vincent Hupertan, MD
Lionel Taksin, MD
Christophe Vaessen, MD
Emmanuel Chartier-Kastler, MD, PhD
Marc-Olivier Bitker, MD, PhD
Morgan Rouprêt, MD, PhD
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1457-6

Weitere Artikel der Ausgabe 4/2011

Annals of Surgical Oncology 4/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.